Sadaf Ghaem-Maghami
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sadaf Ghaem-Maghami has a total of 699 co-authors. Here are the top co-authors by number of shared publications:
Lynsey M. Whilding
26 shared publications- David L. Phelps
Department of Gynaecological Oncology, University Hospital Southampton, Coxford Road, Southampton SO16 5YA, UK
24 shared publications Roberto Dina
24 shared publications- Wei Dai
University of Hong Kong
20 shared publications - Christian J. Maine
Department of Immunology and Microbial Sciences, The Scripps Research Institute, La Jolla, CA 92037
19 shared publications Giorgia Trevisan
19 shared publications
Latest Publications
- Open Access
The Oncological Follow-Up of Fertility Sparing Surgery for Mucinous Borderline Ovarian Tumours: A Retrospective Cohort Study
Background/Objectives: To determine whether long-term oncological follow-up is required following fertility-sparing surgery (FSS) for mucinous borderline ovarian tumours (MBOTs). Methods: A retrospective cohort study set in the tertiary gynaecology oncology centre at Imperial College Healthcare NHS Trust. Patients included were those under follow-up post-surgery for an MBOT in the ovarian clinic from 2007 to 2025. Rate of recurrence was compared amongst patients who underwent ovarian cystectomy, unilateral salpingo-oophorectomy (USO) or bilateral salpingo-oophorectomy (BSO) +/− hysterectomy. Results: From 74 patients diagnosed with MBOT, 36.5% (27/74) underwent BSO +/− hysterectomy and 63.5% (47/74) had FSS. Of the patients who underwent FSS, 59.6% (28/47) had an initial USO and 40.4% (19/47) underwent ovarian cystectomy. Subsequently, 63.2% (12/19) of patients who initially had ovarian cystectomy proceeded with completion USO, leading to a total of 40 USOs performed. There were no recurrences following BSO +/− hysterectomy, primary USO or completion USO after a median follow-up of 49.0, 65.5 and 48.0 months, respectively. Of the patients who underwent ovarian cystectomy, 15.8% (3/19) were found to have residual MBOT (n = 1) two months post-cystectomy or MBOT recurrence (n = 2) at 10- and 66-months post-cystectomy, all diagnosed at USO. There is a significant association between ovarian cystectomy and disease recurrence (Fisher’s exact test p = 0.015). Conclusions: Patients of reproductive age who undergo USO for a MBOT can be offered a reduced follow-up schedule as the risk of recurrence is very low. In contrast, patients who are managed by ovarian cystectomy have a higher risk of recurrence and require long-term surveillance monitoring.
Open AccessThe Oncological Follow-Up of Fertility Sparing Surgery for Mucinous Borderline Ovarian Tumours: A Retrospective Cohort Study
Background/Objectives: To determine whether long-term oncological follow-up is required following fertility-sparing surgery (FSS) for mucinous borderline ovarian tumours (MBOTs). Methods: A retrospective cohort study set in the tertiary gynaecology oncology centre at Imperial College Healthcare NHS Trust. Patients included were those under follow-up post-surgery for an MBOT in the ovarian clinic from 2007 to 2025. Rate of recurrence was compared amongst patients who underwent ovarian cystectomy, unilateral salpingo-oophorectomy (USO) or bilateral salpingo-oophorectomy (BSO) +/− hysterectomy. Results: From 74 patients diagnosed with MBOT, 36.5% (27/74) underwent BSO +/− hysterectomy and 63.5% (47/74) had FSS. Of the patients who underwent FSS, 59.6% (28/47) had an initial USO and 40.4% (19/47) underwent ovarian cystectomy. Subsequently, 63.2% (12/19) of patients who initially had ovarian cystectomy proceeded with completion USO, leading to a total of 40 USOs performed. There were no recurrences following BSO +/− hysterectomy, primary USO or completion USO after a median follow-up of 49.0, 65.5 and 48.0 months, respectively. Of the patients who underwent ovarian cystectomy, 15.8% (3/19) were found to have residual MBOT (n = 1) two months post-cystectomy or MBOT recurrence (n = 2) at 10- and 66-months post-cystectomy, all diagnosed at USO. There is a significant association between ovarian cystectomy and disease recurrence (Fisher’s exact test p = 0.015). Conclusions: Patients of reproductive age who undergo USO for a MBOT can be offered a reduced follow-up schedule as the risk of recurrence is very low. In contrast, patients who are managed by ovarian cystectomy have a higher risk of recurrence and require long-term surveillance monitoring.
- Open Access
- 3 November 2025
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 53 (4) , 2414-2426
Diagnostic performance of quantitative measures from [18F]FDG PET/CT, [18F]FEC PET/CT, and DW-MRI in the detection of lymph node metastases in endometrial and cervical cancer: data from the MAPPING study
Purpose: To evaluate the diagnostic performance of quantitative measures derived from [ 18 F]FDG PET/CT, [ 18 F]FEC PET/CT, and DW-MRI in the detection of lymph node metastases in endometrial and cervical cancer with comparison to standard visual PET analysis with histology as the reference standard. Methods: Subanalysis of quantitative data from the prospective multicentre MAPPING study. Nodal and tumour SUV max from [ 18 F]FDG PET/CT and [ 18 F]FEC PET/CT and ADC mean from DW-MRI were documented. Nodal-to-tumour ratios (NTR) and SUV max -to-ADC mean ratio (STAR) were calculated. Optimal cut-offs of quantitative measures were compared to visual assessment on a regional basis using histopathology as the reference standard. Results: Scans from 112 patients (36 cervical and 76 endometrial cancers; 340 nodal regions) were eligible for quantitative image analysis. Lower ADC mean on DW-MRI was observed in metastatic nodes for cervical cancer but not for endometrial cancer. Quantitative measures were significantly higher in malignant than benign nodal regions on [ 18 F]FDG PET/CT and [ 18 F]FEC PET/CT in endometrial cancer. SUV max cut-offs showed similar performance to visual assessment in the diagnosis of metastatic lymph nodes in endometrial cancer whilst ADC mean cut-offs showed significantly lower specificity than visual assessment. Interobserver agreement was excellent for SUV max measurements on both [ 18 F]FDG PET/CT and [ 18 F]FEC PET/CT, but poor for ADC mean on DW-MRI. Conclusion: Quantitative measures from [ 18 F]FDG PET/CT, [ 18 F]FEC PET/CT, or DW-MRI did not outperform visual assessment in the detection of nodal metastases in endometrial cancer. Therefore, the implementation of these quantitative measures as standalone diagnostic tools in routine clinical practice is not recommended.
- 3 November 2025
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 53 (4) , 2414-2426
Open AccessDiagnostic performance of quantitative measures from [18F]FDG PET/CT, [18F]FEC PET/CT, and DW-MRI in the detection of lymph node metastases in endometrial and cervical cancer: data from the MAPPING study
Purpose: To evaluate the diagnostic performance of quantitative measures derived from [ 18 F]FDG PET/CT, [ 18 F]FEC PET/CT, and DW-MRI in the detection of lymph node metastases in endometrial and cervical cancer with comparison to standard visual PET analysis with histology as the reference standard. Methods: Subanalysis of quantitative data from the prospective multicentre MAPPING study. Nodal and tumour SUV max from [ 18 F]FDG PET/CT and [ 18 F]FEC PET/CT and ADC mean from DW-MRI were documented. Nodal-to-tumour ratios (NTR) and SUV max -to-ADC mean ratio (STAR) were calculated. Optimal cut-offs of quantitative measures were compared to visual assessment on a regional basis using histopathology as the reference standard. Results: Scans from 112 patients (36 cervical and 76 endometrial cancers; 340 nodal regions) were eligible for quantitative image analysis. Lower ADC mean on DW-MRI was observed in metastatic nodes for cervical cancer but not for endometrial cancer. Quantitative measures were significantly higher in malignant than benign nodal regions on [ 18 F]FDG PET/CT and [ 18 F]FEC PET/CT in endometrial cancer. SUV max cut-offs showed similar performance to visual assessment in the diagnosis of metastatic lymph nodes in endometrial cancer whilst ADC mean cut-offs showed significantly lower specificity than visual assessment. Interobserver agreement was excellent for SUV max measurements on both [ 18 F]FDG PET/CT and [ 18 F]FEC PET/CT, but poor for ADC mean on DW-MRI. Conclusion: Quantitative measures from [ 18 F]FDG PET/CT, [ 18 F]FEC PET/CT, or DW-MRI did not outperform visual assessment in the detection of nodal metastases in endometrial cancer. Therefore, the implementation of these quantitative measures as standalone diagnostic tools in routine clinical practice is not recommended.
- Open Access
- 29 November 2024
- Published by Taylor & Francis in Future Oncology
- Vol. 21 (3) , 341-347
Homologous recombination deficiency testing in patients with high grade ovarian cancer: factors influencing test success
Testing for tumor BRCA mutations and homologous recombination deficiency (HRD) is recommended for all patients with advanced high-grade epithelial ovarian cancer. Delays in the HRD testing process can significantly affect the treatment offered to patients. HRD testing pathways and sampling processes were analyzed for tests sent from a tertiary gynae-oncology referral center between December 2020 and January 2023. A total of 148 hRD tests were performed in 125 patients. The overall success rate of HRD testing was 69.6%. The success rates of obtaining results were: from diagnostic image-guided biopsy 66.7% (n = 40/60), at primary surgery 91.5% (n = 42/47), and at interval debulking surgery 51.2% (n = 21/41). The use of a larger 16-gauge needle used at image-guided biopsy produced a 100% success rate. Of 148 tests carried out, the median time for result was 28 days (range 14-158 days), with only 27% returned results in 21 or fewer days. In successful tests, 44.7% were classified as HRD-positive. 97% of patients with HRD-positive tumors treated at the center received a PARP inhibitor as part of their first-line maintenance treatment. By optimizing the factors affecting HRD test success, we can obtain faster results and offer patients appropriate treatment at earlier time points to improve patient outcomes.
- 29 November 2024
- Published by Taylor & Francis in Future Oncology
- Vol. 21 (3) , 341-347
Open AccessHomologous recombination deficiency testing in patients with high grade ovarian cancer: factors influencing test success
Testing for tumor BRCA mutations and homologous recombination deficiency (HRD) is recommended for all patients with advanced high-grade epithelial ovarian cancer. Delays in the HRD testing process can significantly affect the treatment offered to patients. HRD testing pathways and sampling processes were analyzed for tests sent from a tertiary gynae-oncology referral center between December 2020 and January 2023. A total of 148 hRD tests were performed in 125 patients. The overall success rate of HRD testing was 69.6%. The success rates of obtaining results were: from diagnostic image-guided biopsy 66.7% (n = 40/60), at primary surgery 91.5% (n = 42/47), and at interval debulking surgery 51.2% (n = 21/41). The use of a larger 16-gauge needle used at image-guided biopsy produced a 100% success rate. Of 148 tests carried out, the median time for result was 28 days (range 14-158 days), with only 27% returned results in 21 or fewer days. In successful tests, 44.7% were classified as HRD-positive. 97% of patients with HRD-positive tumors treated at the center received a PARP inhibitor as part of their first-line maintenance treatment. By optimizing the factors affecting HRD test success, we can obtain faster results and offer patients appropriate treatment at earlier time points to improve patient outcomes.
- Open Access
- 21 March 2024
- Published by JMIR Publications Inc. in JMIR Cancer
- Vol. 11, e58657
Understanding and addressing challenges with Electronic Health Record use in gynaecological oncology: a cross-sectional survey of multidisciplinary professionals in the United Kingdom and co-design of an integrated informatics platform to support clinical decision making. (Preprint)
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: The benefits and challenges of Electronic Health Record (EHR) use may be particularly significant in complex, high-risk specialties such as gynaecological oncology, yet few studies address the experiences of end-users. Objective: This study aimed to explore perspectives on EHR use in gynaecological oncology and to develop an informatics platform for ovarian cancer. Methods: A cross-sectional survey was conducted using a web-based questionnaire to capture UK professional experiences of EHR use. Free-text responses were analysed using content analysis; counts and proportions were calculated for quantitative data. An informatics platform was co-designed using human-centred design. Natural language processing was used to extract genomic results and operative details from free-text documentation. Results: Of 92 respondents, 84 (92.3%) access multiple electronic systems for clinical decision-making, with 28.6% (26/91) using ≥5 EHR systems. Around 17% (16/92) spend more than 50% of their clinical time looking for information in the EHR. Key challenges relate to fragmentation of the patient record across disparate systems meaning retrieval of pertinent information is often time-consuming. The main benefit of EHR use was perceived to be ease-of-access to patient information, yet 60.0% (54/90) of respondents do not have access to individual patient summaries. Our co-designed ovarian cancer informatics platform brings together patient data from different electronic systems and displays it in a single location to support clinical decision making. Conclusions: EHR systems are not currently optimised to support decision-making in gynae-oncology. Co-designed clinical decision support tools could address challenges with data fragmentation and information retrieval towards improvements in the quality and safety of cancer care.
- 21 March 2024
- Published by JMIR Publications Inc. in JMIR Cancer
- Vol. 11, e58657
Open AccessUnderstanding and addressing challenges with Electronic Health Record use in gynaecological oncology: a cross-sectional survey of multidisciplinary professionals in the United Kingdom and co-design of an integrated informatics platform to support clinical decision making. (Preprint)
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: The benefits and challenges of Electronic Health Record (EHR) use may be particularly significant in complex, high-risk specialties such as gynaecological oncology, yet few studies address the experiences of end-users. Objective: This study aimed to explore perspectives on EHR use in gynaecological oncology and to develop an informatics platform for ovarian cancer. Methods: A cross-sectional survey was conducted using a web-based questionnaire to capture UK professional experiences of EHR use. Free-text responses were analysed using content analysis; counts and proportions were calculated for quantitative data. An informatics platform was co-designed using human-centred design. Natural language processing was used to extract genomic results and operative details from free-text documentation. Results: Of 92 respondents, 84 (92.3%) access multiple electronic systems for clinical decision-making, with 28.6% (26/91) using ≥5 EHR systems. Around 17% (16/92) spend more than 50% of their clinical time looking for information in the EHR. Key challenges relate to fragmentation of the patient record across disparate systems meaning retrieval of pertinent information is often time-consuming. The main benefit of EHR use was perceived to be ease-of-access to patient information, yet 60.0% (54/90) of respondents do not have access to individual patient summaries. Our co-designed ovarian cancer informatics platform brings together patient data from different electronic systems and displays it in a single location to support clinical decision making. Conclusions: EHR systems are not currently optimised to support decision-making in gynae-oncology. Co-designed clinical decision support tools could address challenges with data fragmentation and information retrieval towards improvements in the quality and safety of cancer care.
- Open Access
Prediction of Deep Myometrial Infiltration, Clinical Risk Category, Histological Type, and Lymphovascular Space Invasion in Women with Endometrial Cancer Based on Clinical and T2-Weighted MRI Radiomic Features
Purpose: To predict deep myometrial infiltration (DMI), clinical risk category, histological type, and lymphovascular space invasion (LVSI) in women with endometrial cancer using machine learning classification methods based on clinical and image signatures from T2-weighted MR images. Methods: A training dataset containing 413 patients and an independent testing dataset consisting of 82 cases were employed in this retrospective study. Manual segmentation of the whole tumor volume on sagittal T2-weighted MRI was performed. Clinical and radiomic features were extracted to predict: (i) DMI of endometrial cancer patients, (ii) endometrial cancer clinical high-risk level, (iii) histological subtype of tumor, and (iv) presence of LVSI. A classification model with different automatically selected hyperparameter values was created. The area under the curve (AUC) of the receiver operating characteristic (ROC) curve, F1 score, average recall, and average precision were calculated to evaluate different models. Results: Based on the independent external testing dataset, the AUCs for DMI, high-risk endometrial cancer, endometrial histological type, and LVSI classification were 0.79, 0.82, 0.91, and 0.85, respectively. The corresponding 95% confidence intervals (CI) of the AUCs were [0.69, 0.89], [0.75, 0.91], [0.83, 0.97], and [0.77, 0.93], respectively. Conclusion: It is possible to classify endometrial cancer DMI, risk, histology type, and LVSI using different machine learning methods.
Open AccessPrediction of Deep Myometrial Infiltration, Clinical Risk Category, Histological Type, and Lymphovascular Space Invasion in Women with Endometrial Cancer Based on Clinical and T2-Weighted MRI Radiomic Features
Purpose: To predict deep myometrial infiltration (DMI), clinical risk category, histological type, and lymphovascular space invasion (LVSI) in women with endometrial cancer using machine learning classification methods based on clinical and image signatures from T2-weighted MR images. Methods: A training dataset containing 413 patients and an independent testing dataset consisting of 82 cases were employed in this retrospective study. Manual segmentation of the whole tumor volume on sagittal T2-weighted MRI was performed. Clinical and radiomic features were extracted to predict: (i) DMI of endometrial cancer patients, (ii) endometrial cancer clinical high-risk level, (iii) histological subtype of tumor, and (iv) presence of LVSI. A classification model with different automatically selected hyperparameter values was created. The area under the curve (AUC) of the receiver operating characteristic (ROC) curve, F1 score, average recall, and average precision were calculated to evaluate different models. Results: Based on the independent external testing dataset, the AUCs for DMI, high-risk endometrial cancer, endometrial histological type, and LVSI classification were 0.79, 0.82, 0.91, and 0.85, respectively. The corresponding 95% confidence intervals (CI) of the AUCs were [0.69, 0.89], [0.75, 0.91], [0.83, 0.97], and [0.77, 0.93], respectively. Conclusion: It is possible to classify endometrial cancer DMI, risk, histology type, and LVSI using different machine learning methods.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Clinical Use of Programmed Cell Death-1 and Its Ligand Expression as Discriminatory and Predictive Markers in Ovarian Cancer
Differential expression of immune markers AMCs in patients with benign tumours and EOCs in the discovery set. The percentage of monocytes and lymphocytes (and their subsets) in ascites that expressed PD-1, PD-L1 and CD69 was determined. Analysis of PD-L1+ CD11c+ cells was omitted due to missing data points. Statistical analysis was performed using the Mann-Whitney U test.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Clinical Use of Programmed Cell Death-1 and Its Ligand Expression as Discriminatory and Predictive Markers in Ovarian Cancer
Differential expression of immune markers AMCs in patients with benign tumours and EOCs in the discovery set. The percentage of monocytes and lymphocytes (and their subsets) in ascites that expressed PD-1, PD-L1 and CD69 was determined. Analysis of PD-L1+ CD11c+ cells was omitted due to missing data points. Statistical analysis was performed using the Mann-Whitney U test.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Clinical Use of Programmed Cell Death-1 and Its Ligand Expression as Discriminatory and Predictive Markers in Ovarian Cancer
Differential expression of immune markers on PBMCs in patients with benign tumours and high grade serous (HGS) tumours in the discovery and validation cohorts. A: The percentage of monocytes and lymphocytes (and their subsets) in PBMCs from patients with benign tumours or HGS that expressed PD-1, PD-L1 and CD69 in the discovery set. B: Differential expression of PBMC markers between benign tumours and HGS in the validation set.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Clinical Use of Programmed Cell Death-1 and Its Ligand Expression as Discriminatory and Predictive Markers in Ovarian Cancer
Differential expression of immune markers on PBMCs in patients with benign tumours and high grade serous (HGS) tumours in the discovery and validation cohorts. A: The percentage of monocytes and lymphocytes (and their subsets) in PBMCs from patients with benign tumours or HGS that expressed PD-1, PD-L1 and CD69 in the discovery set. B: Differential expression of PBMC markers between benign tumours and HGS in the validation set.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Clinical Use of Programmed Cell Death-1 and Its Ligand Expression as Discriminatory and Predictive Markers in Ovarian Cancer
Flow cytometry gating for blood and ascites mononuclear cells. Forward and sideward scatter plots were used to set initial gates to identify lymphocytes and granulocyte populations in blood (A) and ascites (B). Dead cell population was identified using PI staining. Subsequent gates were set using isotype controls for all the fluorochromes used so that the bottom left quadrant had at least 99% of the gated cell population. An example of isotype gating for lymphocyte population stained using FITC and PE isotype is shown (C).
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Clinical Use of Programmed Cell Death-1 and Its Ligand Expression as Discriminatory and Predictive Markers in Ovarian Cancer
Flow cytometry gating for blood and ascites mononuclear cells. Forward and sideward scatter plots were used to set initial gates to identify lymphocytes and granulocyte populations in blood (A) and ascites (B). Dead cell population was identified using PI staining. Subsequent gates were set using isotype controls for all the fluorochromes used so that the bottom left quadrant had at least 99% of the gated cell population. An example of isotype gating for lymphocyte population stained using FITC and PE isotype is shown (C).
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Clinical Use of Programmed Cell Death-1 and Its Ligand Expression as Discriminatory and Predictive Markers in Ovarian Cancer
The stability of unsupervised hierarchical clustering of candidate biomarkers A: 23 markers in PBMC samples, B: 22 markers in ascites samples. Healthy controls (HH), benign ovarian tumours (BN), borderline ovarian tumour (BT) and malignant cases (SER: serous; END: endometrioid; CC: clear cell; MU: mucinous). The stability was estimated by pvclust package in R (see method).
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Clinical Use of Programmed Cell Death-1 and Its Ligand Expression as Discriminatory and Predictive Markers in Ovarian Cancer
The stability of unsupervised hierarchical clustering of candidate biomarkers A: 23 markers in PBMC samples, B: 22 markers in ascites samples. Healthy controls (HH), benign ovarian tumours (BN), borderline ovarian tumour (BT) and malignant cases (SER: serous; END: endometrioid; CC: clear cell; MU: mucinous). The stability was estimated by pvclust package in R (see method).